首页> 外文期刊>Journal of Clinical and Diagnostic Research >Efficacy and Tolerability of Levosulipride, Domperidone and Metoclopramide in Patients with Non-Ulcer Functional Dyspepsia: A Comparative Analysis
【24h】

Efficacy and Tolerability of Levosulipride, Domperidone and Metoclopramide in Patients with Non-Ulcer Functional Dyspepsia: A Comparative Analysis

机译:左磺舒必利,多潘立酮和甲氧氯普胺在非溃疡性功能性消化不良患者中的疗效和耐受性:比较分析

获取原文
           

摘要

Objective: This is a prospective, randomized study designed to demonstrate the efficacy of three study drugs (Levosulpiride, Domperidone and Metoclopramide) in Functional Dyspepsia. Subject recruitment was done from medicine outpatient department of the teaching hospital from June 2013 to November 2013. Materials and Methods: The data collection was performed by the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) question instrument for assessing the dyspeptic symptoms of functional dyspepsia in patients enrolled in the study were assessed at base line (Prior to initiation of therapy) and at the next 4 weeks on a 5-point scale.Result: Among 120 patients 113 patients completed this study in three groups (G-1 Levosulpiride 40 patients, G-2 Domperidone 35 patients and G-3 Metoclopramide 38 patients) were followed up. Female gender was dominated (75), occupation wise most of patients belong to laborer (49) class. Highly significant improvement in symptoms scale was noticed in G-1 Levosulpiride 40 patients? group. Conclusion: Functional Gastrointestinal disorders are not serious ailments but have a key impact on quality of life. overall dyspeptic symptom relief rates were significantly high in the Levosulpiride group (p<0.004) as compare to Domperidone and Metoclopramide groups. A proper understanding of disease process by health care personnel and by sufferer is obligatory to enhance the quality of life and daunting the self/over the counter medication in this condition.
机译:目的:这是一项前瞻性随机研究,旨在证明三种研究药物(左磺舒必利,多潘立酮和胃复安)在功能性消化不良中的疗效。受试者的招募时间是2013年6月至2013年11月,从教学医院的医学门诊部进行。材料和方法:数据收集是通过短型利兹消化不良问卷(SF-LDQ)问题仪器进行的,以评估功能性消化不良症状研究入组患者的消化不良在基线(开始治疗之前)和接下来的4周以5分制进行评估。结果:在120例患者中,三组(G-1左磺舒必利)中有113例患者完成了这项研究随访40例,G-2多潘立酮35例,G-3甲氧氯普胺38例。女性占主导地位(75),从职业上看,大多数患者属于劳动者(49)类。在G-1 Levosulpiride 40例患者中观察到症状量表的高度显着改善?组。结论:功能性胃肠疾病不是严重疾病,但对生活质量有关键影响。与多潘立酮和甲氧氯普胺组相比,左苏舒必利组的总体消化不良症状缓解率显着高(p <0.004)。在这种情况下,医护人员和患者必须对疾病的过程有正确的了解,以提高生活质量并使自我/非处方药物受挫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号